An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 11 May 2017
At a glance
- Drugs ABT 555 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 28 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 May 2019.
- 09 Sep 2016 Status changed from not yet recruiting to recruiting.
- 05 Aug 2016 Planned number of patients changed from 60 to 35.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History